FGFR1 and gastric cancer: Ponatinib potently inhibits the kinase activity of FGFR1–4 and had higher inhibitory activity in GC cells with FGFR2 amplification than did other FGFR inhibitors and inhibited the growth of SNU-16 xenograft tumors [50].